Hospira Receives FDA Clearance for Plum 360™ Infusion System

LAKE FOREST, Ill., Jan. 20, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE:  HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that the company has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum 360™ infusion system with Hospira MedNet™ safety software. The newest in Hospira's portfolio of infusion devices, the Plum 360 system builds on the unique air management and secondary delivery features of Plum A+™, while expanding its drug library and wireless capability to enable streamlined electronic medical record (EMR) integration.

"Hospira is excited to announce clearance of the Plum 360 infusion system in the United States -- another important milestone in our continued path to streamline and modernize our device portfolio," said David J. Endicott, president, Hospira Medical Devices. "Hospira will continue to develop and launch the most technologically advanced infusion pumps in the industry for our customers and patients."

The Plum 360 infusion system with Hospira MedNet safety software is designed to help improve the safety and efficiency of intravenous (I.V.) medication administration, with benefits including:

• infusion programming that defaults to the Hospira MedNet drug library for advanced patient safety;
• large drug library capacity with fast keypad drug search for ease of programming;
• improved wireless communication to expedite drug library updates and optimize EMR connectivity with automated programming and documentation;
• smart secondary delivery, so the pump can differentiate between primary and secondary infusion lines and deliver each as intended; and,
• unique air management that doesn't require disconnecting the administration set from the patient to clear the air from the line.

Plum 360 will be fully available to customers in the United States in the coming weeks.

The introduction of Plum 360 with Hospira MedNet is a complementary addition to Hospira's medication management portfolio, which also features products such as the Plum A+™ infusion system; the Sapphire™ ambulatory infusion system*; the recently cleared SapphirePlus™ large-volume general-infusion device*, and the market-leading LifeCare PCA™ pain management pump with Hospira MedNet.

About Hospira
Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Hospira's goals, plans and strategy related to Hospira's global devices. Hospira cautions that these forward-looking statements are subject to risks and uncertainties, including adequate and sustained progress on the company's quality initiatives and device strategy that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, legal, technological, manufacturing supply, quality, modernizing and streamlining activities, and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and subsequent Forms 10-Q, filed with the U.S. Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments, except as required by law.

* Sapphire™ and SapphirePlus™ are trademarks of Q Core Medical Ltd.

SOURCE Hospira, Inc.